Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MTVA
MTVA logo

MTVA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy MetaVia Inc (MTVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.590
1 Day change
2.58%
52 Week Range
23.100
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

MetaVia Inc (MTVA) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financials are weak, with significant declines in net income and EPS, and no positive growth trends. Additionally, there are no strong technical or proprietary trading signals to support a buy decision. The lack of news, trading trends, and positive catalysts further weakens the case for investment.

Technical Analysis

The technical indicators show a bearish trend with moving averages (SMA_200 > SMA_20 > SMA_5). The MACD is positive but contracting, and RSI is neutral at 45.328. The stock is trading near its pivot level of 1.598, with resistance at 1.685 and support at 1.511. Overall, there is no clear bullish signal.

Positive Catalysts

  • NULL identified. There is no recent news, trading trends, or significant positive developments.

Neutral/Negative Catalysts

  • Weak financial performance in Q3 2025, with net income down -40.25% YoY and EPS down -75.04% YoY. No significant trading activity from insiders or hedge funds. Bearish technical indicators and lack of proprietary trading signals.

Financial Performance

In Q3 2025, MetaVia Inc reported no revenue growth (0% YoY), a significant drop in net income (-40.25% YoY), and a sharp decline in EPS (-75.04% YoY). Gross margin remains at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
Wall Street analysts forecast MTVA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.550
sliders
Low
40
Averages
47.5
High
55
Current: 1.550
sliders
Low
40
Averages
47.5
High
55
H.C. Wainwright
Andrew Fein
initiated
$12
AI Analysis
2025-09-04
Reason
H.C. Wainwright
Andrew Fein
Price Target
$12
AI Analysis
2025-09-04
initiated
Reason
H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia with a Buy rating and $12 price target. The firm says Metavia offers a \"compelling opportunity\" in the metabolic disease space based on its two \"differentiated\" pipeline programs.
Maxim
Jason McCarthy
Buy
downgrade
$6 -> $3
2025-05-19
Reason
Maxim
Jason McCarthy
Price Target
$6 -> $3
2025-05-19
downgrade
Buy
Reason
Maxim analyst Jason McCarthy lowered the firm's price target on MetaVia to $3 from $6 and keeps a Buy rating on the shares. The firm cites the company's Q1 results, cash update, and its recent $10M financing in adjusting its model, though it remains positive on MetaVia's obesity (DA-1726) and MASH (DA-1241) treatment opportunities, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MTVA
Unlock Now

People Also Watch